Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human (tested or 100% immunogen sequence identity)
IgG1 Monoclonal [TR9]
Ion exchange chromatography
Specificity and Use
CD36 antibody was raised against platelets.
Reacts with CD36 (GPIIIb), a 85 kD integral membrane glycoprotein expressed on platelets, macrophages, endothelial cells, early erythroid cells and megakaryocytes. The antibody TR9 cross-blocks binding of FITC-labeled standard antibody OKM5. Anti-CD36 antibodies inhibit adhesive functions (e. g. adherence of infected erythrocytes to target cells).
The reagent is designed for Flow Cytometry analysis of human blood cells using 20 ul reagent / 100 ul of whole blood or 106 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests. The applications listed have been tested for the unconjugated form of this product. Other forms have not been tested.
PBS, 15 mM sodium azide, 0.2% high-grade protease free BSA as a stabilizing agent.
Binds to collagen, thrombospondin, anionic phospholipids and oxidized low-density lipoprotein (oxLDL). May function as a cell adhesion molecule. Directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Binds long chain fatty acids and may function in the transport and/or as a regulator of fatty acid transport. Receptor for thombospondins, THBS1 AND THBS2, mediating their antiangiogenic effects.